Correlation of Levels of IL-6 with Tumor Burden and Receptor Status in Patients of Locally Advanced Carcinoma Breast

Goswami, Binita; Mittal, Priya; Gupta, Nikhil

doi:10.1007/s12291-012-0234-7

Cited by 8 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TMB is correlated with clinical outcome in multiple cancer types treated with CPI (65,66). Previous studies indicated that TMB levels correlated with gene mutations in tumors (25,40,67,68). TMB-H has been reported to correlate with the generation of neoantigens and potential clinical responses to immunotherapies (69).…”

Section: Discussionmentioning

confidence: 99%

Comprehensive genomic profile of cholangiocarcinomas in China

Shi

Liu

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a primary malignancy, which is often diagnosed as locally advanced or metastatic. Previous studies have revealed genomic characteristics of CCA in Western patients, however comprehensive genomic features of CCA in Chinese patients have not been well understood. To explore the specific genomic characteristics of Chinese patients with CCA, a total of 66 patients with CCA, including 44 intrahepatic CCA (iCCA) and 22 extrahepatic CCA (exCCA) cases, were studied. The most commonly altered genes in CCAs were TP53 (62.12%, 41/66), KRAS (36.36%, 24/66), SMAD4 (24.24%, 16/66), TERT (21.21%, 14/66), ARID1A (19.70%, 13/66), CDKN2A (19.70%, 13/66), KMT2C (9.09%, 6/66) and RBM10 (9.09%, 6/66), ERBB2 (7.58%, 5/66) and BRAF (7.58%, 5/66). Many gene mutations, including STK11, CCND1 and FGF19, were only found in iCCA. RBM10 mutations were found to be significantly higher in exCCA. The gene mutations of neurofibromin 1, STK11, CCND1 and FBXW7 specifically occurred in males, whereas gene mutations of ERBB2, AXIN2 and CREBBP specifically occurred in females. ERBB2 mutations were significantly associated with the sex of patients with CCA. Mutations in PIK3CA, FGFR2 and ZNF750 were significantly associated with the age of patients with CCA and TERT mutations were significantly associated with tumor differentiation. Alterations in KMT2C, PBRM1, AXIN2, MAGI2, BRCA2 and SPTA1 were associated with tumor mutational burden. The findings of the present study suggest that targeted sequencing, using next-generation sequencing technology, provides comprehensive and accurate information on genomic alterations, which will provide novel potential biomarkers for the diagnosis of CCA and may guide precise therapeutic strategies for Chinese patients with CCA.

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive genomic profile of cholangiocarcinomas in China

Shi

Liu

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Circulating pro-inflammatory cytokines are elevated in various cancer populations prior to any treatment including ovarian cancer (Lutgendorf et al, 2008), colorectal cancer (Belluco et al, 2000), lung cancer (Wojciechowska-Lacka, et al, 1996), breast cancer (Benoy et al, 2002), pancreatic cancer (Okada et al, 1998), gastric cancer (Kim et al, 2003), prostate cancer (Michalaki et al, 2004), head and neck cancer (Riedel et al, 2005), renal cell carcinoma (Yoshida et al, 2002), and bladder cancer (Mahmoud El-Salahy, 2002). High concentrations of circulating inflammatory cytokines such as IL-6 and TNF-α are associated with later stage disease (Belluco et al, 2000; Kim et al, 2003; Kozlowski et al, 2003; Michalaki et al, 2004; Okada et al, 1998; Yoshida et al, 2002), poorly differentiated tumors (Goswami et al, 2013; Kaminska et al, 2005; Ljungberg et al, 1997; Mahmoud El-Salahy, 2002; Yoshida et al, 2002) and tumor size/volume (Chung & Chang, 2003; Kaminska et al, 2005; Plante et al, 1994) in a variety of malignancies. Elevations of circulating pro-inflammatory cytokines have also been associated with less common indices of disease severity including extent of tumor necrosis in colorectal cancer (Guthrie et al, 2013; Richards et al, 2012).…”

Section: Cancer Patients Prior To Treatmentmentioning

confidence: 99%

Pre-treatment effects of peripheral tumors on brain and behavior: Neuroinflammatory mechanisms in humans and rodents

Schrepf¹,

Lutgendorf²,

Pyter³

2015

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

Cancer patients suffer high levels of affective and cognitive disturbances, which have been attributed to diagnosis-related distress, impairment of quality of life, and side effects of primary treatment. An inflammatory microenvironment is also a feature of the vast majority of solid tumors. However, the ability of tumor-associated biological processes to affect the central nervous system (CNS) has only recently been explored in the context of symptoms of depression and cognitive disturbances. In this review, we summarize the burgeoning evidence from rodent cancer models that solid tumors alter neurobiological pathways and subsequent behavioral processes with relevance to affective and cognitive disturbances reported in human cancer populations. We consider, in parallel, the evidence from human clinical cancer research demonstrating that affective and cognitive disturbances are common in some malignancies prior to diagnosis and treatment. We further consider the underlying neurobiological pathways, including altered neuroinflammation, tryptophan metabolism, prostaglandin synthesis and associated neuroanatomical changes, that are most strongly implicated in the rodent literature and supported by analogous evidence from human cancer populations. We focus on the implications of these findings for behavioral researchers and clinicians, with particular emphasis on methodological issues and areas of future research.

show abstract

“…Tumor Necrosis Factor alpha is one of the main cytokines secreted from the adipose tissue that increases the concentration of pro-inflammatory cytokines (CRP and IL-6); as a growth factor, it can induce tumor growth and cancer metastasis (8,9). The IL-6 expression in breast tissue is associated with the grade of the tumor (10,11). Previous studies have shown that, compared to healthy women, breast cancer survivors have higher amounts of circulating cytokines, a disorder that may persist for up to five years after the diagnosis of cancer (12).…”

Section: Introductionmentioning

confidence: 99%